Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1972 1
1975 1
1979 1
1987 1
1988 3
1989 4
1990 2
1991 5
1992 4
1993 1
1994 2
1995 6
1996 2
1997 1
1998 1
1999 1
2000 3
2001 4
2002 4
2003 1
2004 4
2005 9
2006 4
2007 5
2008 3
2009 5
2010 5
2011 1
2012 4
2013 7
2014 9
2015 6
2016 4
2017 5
2018 9
2019 9
2020 6
2021 5
Text availability
Article attribute
Article type
Publication date

Search Results

141 results
Results by year
Filters applied: . Clear all
Page 1
Enthesitis: from pathophysiology to treatment.
Schett G, Lories RJ, D'Agostino MA, Elewaut D, Kirkham B, Soriano ER, McGonagle D. Schett G, et al. Among authors: kirkham b. Nat Rev Rheumatol. 2017 Nov 21;13(12):731-741. doi: 10.1038/nrrheum.2017.188. Nat Rev Rheumatol. 2017. PMID: 29158573 Review.
IL-17 in the immunopathogenesis of spondyloarthritis.
Taams LS, Steel KJA, Srenathan U, Burns LA, Kirkham BW. Taams LS, et al. Among authors: kirkham bw. Nat Rev Rheumatol. 2018 Aug;14(8):453-466. doi: 10.1038/s41584-018-0044-2. Nat Rev Rheumatol. 2018. PMID: 30006601 Review.
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.
Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, Landewé R, Nash P, Pricop L, Yuan J, Richards HB, Mpofu S; FUTURE 1 Study Group. Mease PJ, et al. Among authors: kirkham b. N Engl J Med. 2015 Oct;373(14):1329-39. doi: 10.1056/NEJMoa1412679. N Engl J Med. 2015. PMID: 26422723 Free article. Clinical Trial.
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, van der Heijde D, Landewé R, Conaghan PG, Gottlieb AB, Richards H, Pricop L, Ligozio G, Patekar M, Mpofu S; FUTURE 2 Study Group. McInnes IB, et al. Among authors: kirkham b. Lancet. 2015 Sep 19;386(9999):1137-46. doi: 10.1016/S0140-6736(15)61134-5. Epub 2015 Jun 28. Lancet. 2015. PMID: 26135703 Free article. Clinical Trial.
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, Adams DH, Kerr L, Lee C, Shuler CL, Genovese M; SPIRIT-P2 Study Group. Nash P, et al. Among authors: kirkham b. Lancet. 2017 Jun 10;389(10086):2317-2327. doi: 10.1016/S0140-6736(17)31429-0. Epub 2017 May 24. Lancet. 2017. PMID: 28551073 Clinical Trial.
141 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page